MMWR – Morbidity and Mortality Weekly Report

News Summary for October 13, 2011

1. Prevalence of Coronary Heart Disease — United States, 2006–2010

CDC
Division of News & Electronic Media           
(404) 639-3286

The prevalence of self-reported coronary heart disease in the United States decreased from 6.7 percent in 2006 to 6.0 percent in 2010.  However, rates of decline ranged widely by age, sex, race/ethnicity, education, and state of residence.  And despite overall declines, men, people age 65 and older, individuals with less than high school education, American Indians/Alaska Natives, and residents in states such as West Virginia and Kentucky experienced coronary heart disease at levels well above the general population.  In general, those of young age, women, Asian or Native Hawaiians/other Pacific Islanders, participants with more than college education, and residents of Missouri showed the highest declines. Prevalence of coronary heart disease in the United States still ranges widely by various demographic factors.

2. Progress Toward Implementation of Human Papillomavirus Vaccination — the Americas, 2006–2010

CDC
Division of News & Electronic Media           
(404) 639-3286

Vaccines against HPV have been introduced in four countries in the Americas, and additional countries are planning implementation to prevent cervical and other cancers. Cervical cancer kills over 36,000 women a year in the Americas (North and South America), even though most cases could be prevented with safe and effective vaccines against human papillomavirus (HPV).  This infection causes about 70 percent of cervical cancers as well as other cancers in women and men. A new report published by the CDC and the Pan American Health Organization discusses progress toward HPV vaccine introduction in the Americas, finding that as of January 2011, four (11 percent) of the 35 countries in the Americas included vaccines against HPV in their immunization programs.  These four countries were the United States, Canada, Mexico, and Panama. HPV vaccination coverage varied widely. For the 3-dose vaccine series, coverage measured among girls aged 13–17 years was 32 percent in the United States; in parts of Canada, ≥80 percent coverage was reported among girls in the target age ranges.  The report describes barriers to implementing HPV vaccination programs more widely, including the high cost of HPV vaccines, competing priorities for scarce public health funding, and the challenges of delivering vaccines targeted to adolescents. 

3. Establishment of a Viral Hepatitis Surveillance System — Pakistan, 2009–2011

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
News Media Team
(404) 639-8895

No Summary Available

4. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease

CDC
Division of News & Electronic Media           
(404) 639-3286

This Policy Note outlines the ACIP recommendations for use of Menactra, one of the meningococcal conjugate vaccine products, among children aged 9 through 23 months at increased risk for invasive meningococcal disease. This includes children who have complement component deficiencies (e.g., C5–C9, properdin, factor H, or factor D), children who are traveling to or residents of countries where meningococcal disease is hyperendemic or epidemic, and children who are in a defined risk group during a community or institutional meningococcal outbreak. ACIP recommends that children aged 9 through 23 months with certain risk factors for meningococcal disease receive a 2-dose series of Menactra, 3 months apart.

###
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES